Novartis AG (NYSE:NVS) is reporting third quarter financial results on Tuesday 27th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, NVS is expected to report 3Q20 income of $ 1.45 per share from revenue of $ 12525.60 million.
For the full year, analysts anticipate top line of $ 49613.60 million, while looking forward to income of $ 5.71 per share bottom line.
Previous Quarter Performance
Novartis AG recorded income for the second quarter of $ 1.36 per share, from the revenue of $ 11,347.00 million. The quarterly earnings swell 1.49 percent while revenues dropped 3.54 percent compared with the same quarter last year.
According to street consensus, NVS was expected to report 2Q20 income of $ 1.35 per share from revenue of $ 11998.80 million. The bottom line results beat street analysts by $ 0.01 or 0.74 percent, at the same time, top line results fell short of analysts by $ 651.8 million or 5.43 percent.
Stock Performance
Shares of Novartis AG traded up $ 0.02 or 0.02 percent on Friday, reaching $ 84.43 with volume of 803.50 thousand shares. Novartis AG has traded high as $ 84.88 and has cracked $ 84.12 on the downward trend
According to the previous trading day, closing price of $ 84.43, representing a 22.02 % increase from the 52 week low of $ 69.18 and a 15.45 % decrease over the 52 week high of $ 99.84.
The company has a market capital of $ 192.85 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 1st September 2020, upgraded by Morgan Stanley to Overweight from Equal-Weight rating
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The companys Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
